Navigation Links
Breast Health Study Advances Safety Profile for Soy-Based Natural S-equol Supplement Designed to Manage Menopause Symptoms
Date:9/13/2011

NORTHRIDGE, Calif., Sept. 13, 2011 /PRNewswire/ -- Consuming the soy germ-based compound Natural S-equol and the supplement SE5-OH containing Natural S-equol did not increase the risk of estrogen-sensitive breast cancer, according to a study in the September issue of the peer-reviewed journal Food and Chemical Toxicology.  SE5-OH containing Natural S-equol reduced menopause symptoms in postmenopausal women in previously reported controlled trials in the United States and in Japan.

"A major concern of health care professionals and women in managing menopausal symptoms is that a treatment might increase the risk of developing or progressing breast cancer," said Belinda H. Jenks, Ph.D., Director of Scientific Affairs & Nutrition Education at Pharmavite LLC, the makers of Nature Made® vitamins and minerals and a subsidiary of Otsuka Pharmaceutical Co., Ltd., which supported the study. "This study is the first to directly examine the effects of Natural S-equol alone and SE5-OH containing Natural S-equol, which we are developing to reduce menopause symptoms, directly on the growth of human breast cancer cells in an established mouse model as well as in directly in cell cultures. The study documented that Natural S-equol itself, as well as SE5-OH, did not increase or stimulate the growth of these breast cancer cells."

The safety of SE5-OH containing Natural S-equol previously was confirmed by standard animal testing.  Also, studies involving postmenopausal women who consumed SE5-OH containing Natural S-equol have not observed any safety problems, including analysis of breast and reproductive tissues and of hormone levels, and have documented significant reductions in hot flashes frequency, in muscle and joint discomfort. More information about S-equol and SE5-OH, including study results, is at http://www.naturalequol.
'/>"/>

SOURCE Pharmavite LLC
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Positive Results from Phase 2 Clinical Study of NKTR-102 in Metastatic Breast Cancer Presented in Oral Session at the ASCO 2011 Breast Cancer Symposium
2. Naviscan Receives CE Mark Approval for High-Resolution Breast PET and PET-Guided Biopsy
3. Boehringer Ingelheim Broadens Its Breast Cancer Clinical Trial Program for the Investigational Compound Afatinib
4. SimonMed and Cox Business Bring Breast Tomosynthesis to Arizona
5. Generex Subsidiary Antigen Express Provides Update on Phase 2 Breast Cancer Immunotherapy Program
6. International St. Gallen Expert Panel Highlights Importance of Molecular Subtyping in Breast Cancer Treatment
7. SIUH Offers New 5-Day Breast Cancer Therapy
8. Siemens Partners with American Cancer Society to Make Strides Against Breast Cancer
9. Medela Announces 2011 Breastfeeding Hall of Excellence Inductees to Nationally Recognize Exceptional Breastfeeding Advocates
10. Evergreen Hospital Launches Revolutionary Breast Cancer Detection and Diagnostic Imaging Technology
11. A Simple Way to Detect Breast Cancer at Stage 0 Discovered
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... -- Ellen MacArthur Foundation meddelade i ... kommer att vara en partner för att hjälpa ... Efter stiftelsens framgångsrika partnerskap med Renault, BT/Cisco ... att ansluta sig som partner för att få ... verksamhet och stödja stiftelsens arbete inom utbildning. ...
(Date:6/19/2013)... , June 19, 2013 The Physician-Patient Alliance ... alarm fatigue. The need to urgently address this ... its Sentinel Event Alert #50 , "Medical device alarm safety ... database, between January 2008 and June 2012, there were 98 ... resulted in death (82%) , 13 resulted in permanent ...
(Date:6/19/2013)...   BioCision , a leader in advanced ... many areas of medical and scientific research, announced ... U.S. Patent Office that apply to two of ... handling to ensure the consistency of test conditions ... Patent number 8,388,912 covers CoolSink® ...
Breaking Medicine Technology:Ellen MacArthur Foundation presenterar Philips som global partner vid det konstituerande internationella toppmötet om cirkulär ekonomi 2Ellen MacArthur Foundation presenterar Philips som global partner vid det konstituerande internationella toppmötet om cirkulär ekonomi 3Three Lessons Learned to Reduce Alarm Fatigue and Improve Alarm Management and Patient Safety in Hospitals 2Three Lessons Learned to Reduce Alarm Fatigue and Improve Alarm Management and Patient Safety in Hospitals 3BioCision Announces Two New U.S. Patents for Thermo-Conductive Products that Standardize Sample Handling in Laboratory Research 2
... Inc. (Nasdaq: KERX ) today announced that ... from previous clinical trials of Zerenex™ (ferric citrate) were ... the American Society of Nephrology (ASN) Kidney Week 2011 ... ferric iron-based drug candidate, is currently in Phase 3 ...
... and WASHINGTON, Nov. 14, 2011 Nektar Therapeutics (NASDAQ: ... data for NKTR-192, a novel mu-opioid agonist, was presented ... Neuroscience being held November 12-16, 2011 in Washington, DC. ... for the treatment of acute pain.  It is designed ...
Cached Medicine Technology:Keryx Biopharmaceuticals Announces Highlights from Zerenex™ (ferric citrate) Poster Presentations at American Society of Nephrology Kidney Week 2011 Annual Meeting 2Keryx Biopharmaceuticals Announces Highlights from Zerenex™ (ferric citrate) Poster Presentations at American Society of Nephrology Kidney Week 2011 Annual Meeting 3Keryx Biopharmaceuticals Announces Highlights from Zerenex™ (ferric citrate) Poster Presentations at American Society of Nephrology Kidney Week 2011 Annual Meeting 4Positive Data for Nektar's New Mu-Opioid Analgesic Molecule to Treat Acute Pain Highlighted at Neuroscience 2011 2Positive Data for Nektar's New Mu-Opioid Analgesic Molecule to Treat Acute Pain Highlighted at Neuroscience 2011 3Positive Data for Nektar's New Mu-Opioid Analgesic Molecule to Treat Acute Pain Highlighted at Neuroscience 2011 4Positive Data for Nektar's New Mu-Opioid Analgesic Molecule to Treat Acute Pain Highlighted at Neuroscience 2011 5Positive Data for Nektar's New Mu-Opioid Analgesic Molecule to Treat Acute Pain Highlighted at Neuroscience 2011 6
(Date:6/19/2013)... 19, 2013 The Journal of Parasitology ... today’s computer software, it creates questions of ethics. For ... As an already published case shows, scientific publications need ... The Journal of Parasitology features a ... a 2004 article published in the Journal of the ...
(Date:6/19/2013)... HOUSTON - In a major international study led by ... Center, the targeted therapy ibrutinib continues to show remarkable ... cell lymphoma (MCL). , The most recent interim findings ... in the New England Journal of Medicine . ... the 54th American Society of Hematology Annual Meeting and ...
(Date:6/19/2013)... published in the June 19 online edition of the ... researchers from the University of California, San Diego School ... take place when cardiac regeneration occurs in zebrafish after ... various cell lines in the heart are more plastic, ... previously thought. , More importantly, the research reveals a ...
(Date:6/19/2013)... understanding of the genetic process that can lead to ... lesions for some women, and also raises a warning ... cases suggesting they could actually trigger the cancer ... a clearer picture of the chromosomal and genetic changes ... to chronic infection and, in less than 1 percent ...
(Date:6/19/2013)... University of Iowa study reveals significant disparities between ... completing substance abuse treatment programs. Moreover, these disparities ... "Our findings suggest that for most states there,s ... of psychiatry and biostatistics. "There are strong racial ... to complete substance abuse treatment programs successfully, and ...
Breaking Medicine News(10 mins):Health News:Altered Photo in Journal Article Illustrates the Need for Manipulation Guidelines 2Health News:Ibrutinib continues strong showing against mantle cell lymphoma 2Health News:Fate of the heart: Researchers track cellular events leading to cardiac regeneration 2Health News:Genetics of cervical cancer raise concern about antiviral therapy in some cases 2Health News:States vary widely on success rates for minorities in drug treatment programs 2Health News:States vary widely on success rates for minorities in drug treatment programs 3
... out-of-pocket health care costs, CAMP HILL, Pa., Sept. ... to help consumers compare health plan options and,choose one ... is available,to consumers on Highmark member Web sites. ... said Kim,Bellard, Vice President of eMarketing and Customer Relationship ...
... President, SEIU-UHW and SEIU California State ... ... My name is Sal Rosselli,and I,m the President of SEIU United ... workers in healthcare, the,public sector, property services, and other industries throughout ...
... choices , MONDAY, Sept. 10 (HealthDay News) -- U.S. and ... a comprehensive recommendation on how much of what types of ... diets. , Both the American Dietetic Association and the Dietitians ... that 20 percent to 30 percent of energy needs should ...
... -- In lifesaving procedures to open blocked heart arteries ... use of the more expensive drug, abciximab, justified over ... Mayo Clinic study to be published in the current ... and now available as an e-publication, offers clinicians the ...
... Hundreds of Institutional Investors to Attend Conference, ... Board: SKVI / Website: http://www.skinvisible.com ), the ... topically,applied dermatology products, today announced that Mr. Terry ... annual Merriman Curhan Ford & Co.,Investor Summit on ...
... Through November 2007 -, GLENDALE, Calif., ... for applications for the 2008-2009 PowerBar Team ... athletes, coaches,nutritionists, trainers and health and fitness ... invited to visit, http://www.powerbar.com/teamelite/application to submit ...
Cached Medicine News:Health News:Highmark Blue Shield Introduces New Health Plan Comparison Tool for Consumers 2Health News:SEIU Endorses AB 8, 'An Opportunity to Make History' 2Health News:Experts Sort Out Good Fats From Bad 2Health News:Skinvisible to Present at Merriman Curhan Ford & Co.'s Investor Summit 2007 2Health News:PowerBar Issues Open Call for 2008-2009 PowerBar Team Elite(TM) Athlete Sponsorship Program 2
... MacularProtect Complete® is a scientifically ... protection for macular and full body ... the AREDS clinical trial and other ... multinutrient component that provides a broad ...
... formulation that provides the foundation for ... eye-specific nutritional support. All ingredients in ... when applicable. ScienceBased Health formulations are ... bioavailability, and are free of artificial ...
HydroEye is an exclusive formulation designed to provide dry eye relief and support the body's natural tear formation. Like all ScienceBased Health formulations, it is produced in softgel form for ma...
Online Unity Interlaboratory QC Data Management...
Medicine Products: